ArticleCureus2025
Left Subclavian Vein Stenosis Secondary to Central Venous Access Placement: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous stenosis secondary to central venous access is a well-recognized complication. However, in patients without kidney disease or those not undergoing hemodialysis, central venous stenosis is less frequently reported, suggesting that while the condition is documented in these specific populations, it may be underreported in the general population with other characteristics. This study describes a 69-year-old patient with a history of thrombophilia due to MTHRF 677 gene heterozygous mutation, who developed left subclavian vein stenosis two weeks after the use of central vascular access, leading to left upper extremity edema, development of collateral venous network, and pain and dyspnea. Endovascular treatment was performed with recanalization and angioplasty of the subclavian vein, with favorable outcomes, improving symptoms in the immediate post-operative period and continuing through six-month follow-up with monthly consultation and phlebography control. The adequate response to this type of clinical situation with endovascular management and monotherapy with anticoagulant factor Xa inhibitor (apixaban) confirms this approach as another alternative within the field of vascular surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.